Founded Date: 1985-01-01
Total Funding: 36800000.0
Investor Type: Company
Employee Number: 51-100
Investment Stage: N/A
Funding Status: IPO
Number Of Exists: Post-IPO Equity
Technology: Cancer
Last Funding Type: Post-IPO Equity
Investors Number: 4.0
Last Funding Date: 2015-03-12
Industry: End-to-End Drug Development
Headquarters: Hackensack, New Jersey, United States
Estimated Revenue: $1M to $10M